October 29, 2006 - 2:34pm
On October 25, 2006 the Food and Drug Administration approved Tyzeka (telbivudine), manufactured by Novartis, for treatment of chronic hepatitis B.
Tyzeka, a tablet taken once daily, suppresses the hepatitis B virus. Tyzeka is not a cure but is indicated for long-term management of the infection.
The FDA estimates that 70,000 Americans become infected with hepatitis B every year. The virus is blood borne and spreads by sexual contact or blood contamination. The virus causes lifelong infection and serious liver damage. Ultimately liver cancer or liver failure may result.
Tyzeka will be distributed by Idenix Pharmaceuticals of Cambridge, Massachusetts.
Pill Identification - Tyzeka
600 mg: White to slightly yellowish film-coated oval tablets imprinted with LDT on one side
For more information, please see the Novartis press release.
Patient Information - TYZEKA
